U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB

(MARK ONE)

         [X]    QUARTERLY REPORT  UNDER  SECTION 13 OR 15(d)  OF  THE SECURITIES
                EXCHANGE ACT OF 1934

                    For the quarter ended September 30, 2000
                                          ------------------

         [ ]    TRANSITION  REPORT  UNDER  SECTION 13 OR A5(d) OF THE SECURITIES
                EXCHANGE ACT OF 1934  (no fee required)



                         Commission file number 0-23544
                                                -------

                         HUMAN PHEROMONE SCIENCES, INC.
                 -----------------------------------------------
                 (Name of small business issuer in its charter)

                  California                                      94-3107202
-------------------------------------------------         ----------------------
        (State or other jurisdiction of                      (I.R.S. employee)
         incorporation or organization                      Identification No.)


47650 Fremont Blvd.  Suite 200, Fremont, California               94538
----------------------------------------------------      ----------------------
     (Address of principal executive offices)                   (Zip code)


                    Issuer's telephone number: (510) 226-6874

         Check whether the Issuer (1) filed all reports  required to be filed by
Section 13 or 15(d) of the  Exchange  Act during the past 12 months (or for such
shorter period that the  registrant was required to file such reports),  and (2)
has been subject to such filing  requirements for the past 90 days.
                                                                Yes [X]   No [ ]

                   (APPLICABLE ONLY TO CORPORATE REGISTRANTS)

         State the number of shares  outstanding of each of the issuer's classes
of common equity, as of the latest practicable date.  3,429,839 shares of Common
Stock as of November 7, 2000.


                                       1
<PAGE>




                         HUMAN PHEROMONE SCIENCES, INC.
<TABLE>
                                      INDEX
<CAPTION>
                                                                                                             Page
<S>       <C>                                                                                                 <C>
PART I
FINANCIAL INFORMATION

         Item 1. Financial Statements

                  Consolidated Balance Sheets as of September 30, 2000 (Unaudited)
                  and December 31, 1999........................................................................4

                  Consolidated Statements of Operations and Comprehensive Loss (Unaudited) for the
                  Three and Nine Months Ended September 30, 2000 and 1999..................................... 5

                  Consolidated Statements of Cash Flows (Unaudited) for the Nine Months
                  Ended September 30, 2000 and 1999 ...........................................................6

                  Notes to Consolidated Financial Statements (Unaudited).......................................7

         Item 2. Management's Discussion and Analysis

                  Management's Discussion and Analysis of Financial Condition and Results of Operations........9

PART II
OTHER INFORMATION

         Item 6. Exhibits and Reports on Form 8-K.............................................................13

SIGNATURES....................................................................................................14
</TABLE>

                                                          2
<PAGE>


                                     PART I

                              FINANCIAL INFORMATION

Item 1.  Financial Statements






                                       3
<PAGE>

<TABLE>
                                              Human Pheromone Sciences, Inc.

                                                Consolidated Balance Sheets
<CAPTION>
                                                                    September 30, December 31,
(in thousands except share data)                                        2000          1999
------------------------------------------------------------------    --------      --------
                                                                    (unaudited)
<S>                                                                   <C>           <C>
Assets

Current assets:
  Cash and cash equivalents
                                                                      $    953      $    108
  Accounts receivable, net of allowances of $54
   and $338 in 2000 and 1999, respectively                                 968         2,050
  Inventories                                                              368         2,304
  Other current assets                                                      51            36
                                                                      --------      --------
Total current assets                                                     2,340         4,498
Property and equipment, net                                                 19            14
                                                                      --------      --------
                                                                      $  2,359      $  4,512
                                                                      ========      ========

Liabilities and Shareholders' Equity

Current liabilities:
  Bank borrowings                                                     $      0      $    900
  Accounts payable                                                         119           573
  Deferred revenue                                                          94             0
  Accrued advertising                                                       24           313
  Accrued commissions                                                        5           286
  Other accrued expenses                                                   108           374
                                                                      --------      --------
Total current liabilities                                                  350         2,446
                                                                      --------      --------
Commitments and Contingencies

Shareholders' equity:
  Preferred stock, issuable in series, no par value, 10,000,000
  sharesauthorized, 1,433,333 Series AA convertible shares issued
  and outstanding at September 30, 2000 and December 31, 1999,
  18,159 and 14,203  Series BB  convertible  shares issued and
  outstanding  at September 30, 2000 and December 31, 1999,
  respectively                                                           3,706         3,296
Common stock, no par value, 13,333,333  shares  authorized,
  3,429,839 shares issued and outstanding on each date                  17,667        17,667
  Accumulated deficit                                                  (19,286)      (18,847)
  Accumulated other comprehensive loss                                     (78)          (50)
                                                                      --------      --------
Total shareholders' equity                                               2,009         2,066
                                                                      --------      --------
                                                                      $  2,359      $  4,512
                                                                      ========      ========
<FN>
See accompanying notes to consolidated financial statements
</FN>
</TABLE>


                                       4
<PAGE>


                                 Human Pheromone Sciences, Inc.
<TABLE>
                      Consolidated Statements of Operations and Comprehensive Loss
                                         (unaudited)
<CAPTION>
                                                       Three months ended        Nine months ended
                                                      --------------------      --------------------
                                                          September, 30           September  30,
                                                      --------------------      --------------------
<S>                                                   <C>          <C>          <C>          <C>
(in thousands except per share data)                     2000         1999         2000         1999
                                                      -------      -------      -------      -------
Net product sales                                     $   219      $ 1,892      $ 1,974      $ 5,778
License and supply revenues                               282          232          811          696
                                                      -------      -------      -------      -------
Net revenues                                              501        2,124        2,785        6,474
Cost of goods sold                                        170          920          856        2,456
                                                      -------      -------      -------      -------
Gross profit                                              331        1,204        1,929        4,018
Operating Expenses:
   Research and development                                80           82          241          249
   Selling, general and administrative                    330        1,195        2,108        4,396
                                                      -------      -------      -------      -------
Total operating expenses                                  410        1,277        2,349        4,645
                                                      -------      -------      -------      -------
Loss from operations                                      (79)         (73)        (420)        (627)
Other income and (expense)                                                                         0
   Interest income (expense)                                6          (24)         (16)         (70)
   Other income (expense)                                  (6)           2           (4)          (5)
                                                      -------      -------      -------      -------
Total other income and (expense)                         --            (22)         (20)         (75)
                                                      -------      -------      -------      -------
Net loss available to common shareholders                 (79)         (95)        (440)        (702)
Other comprehensive loss - translation adjustment
                                                          (18)          11          (28)         (37)
                                                      -------      -------      -------      -------
Comprehensive loss                                    $   (97)     $   (84)     $  (468)     $  (739)
                                                      =======      =======      =======      =======


                                                      =======      =======      =======      =======
Net loss per common share-basic and diluted           $  (.02)     $  (.03)     $  (.13)     $  (.20)
                                                      =======      =======      =======      =======

Weighted average common shares outstanding              3,430        3,430        3,430        3,430
                                                      =======      =======      =======      =======
<FN>
See accompanying notes to consolidated financial statements
</FN>
</TABLE>


                                       5
<PAGE>


                         Human Pheromone Sciences, Inc.

                      Consolidated Statements of Cash Flows
                                   (unaudited)



                                                             Nine months ended
                                                               September 30,
                                                           ---------------------
(in thousands)                                                2000         1999
                                                           --------     --------


Cash flows from operating activities

Net loss                                                   $  (440)     $  (702)
Adjustments to reconcile net loss
  to net cash provided by (used in) operating activities:
  Depreciation and amortization                                 10           35
  Provision for sales returns and allowances                  (284)        (551)

  Changes in operating assets and liabilities:
    Accounts receivable                                      1,366          663
    Inventories                                              1,936          157
    Other current assets                                       (15)         (41)
    Deferred revenue                                            94         --
Accounts payable and accrued liabilities                    (1,289)        (469)
                                                           --------     --------
Net cash provided by (used in) operating activities          1,378         (908)
                                                           --------     --------
Cash flows from investing activities
  Purchase of property and equipment                           (15)        --
                                                           --------     --------
Net cash used in investing activities                          (15)        --
                                                           --------     --------

Cash flows from financing activities
  Proceeds from bank borrowings                                150        1,510
  Repayment of bank borrowings                              (1,050)      (1,084)

  Proceeds from issuance of convertible preferred stock        410          500
                                                           --------     --------
Net cash (used in) provided by financing activities           (490)         926
                                                           --------     --------

Effect of exchange rate changes on cash                        (28)         (37)
                                                           --------     --------

Net increase in cash and cash equivalents                      845          (19)
Cash and cash equivalents at beginning of period               108           77
                                                           --------     --------
Cash and cash equivalents at end of period                 $   953      $    58
                                                           ========     ========
Cash paid for interest                                     $    24      $    46
                                                           ========     ========

See accompanying notes to consolidated financial statements


                                       6
<PAGE>


                         Human Pheromone Sciences, Inc.

                   Notes to Consolidated Financial Statements
                                   (unaudited)

                               September 30, 2000

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization and Nature of Operations

         Human Pheromone Sciences,  Inc. (the "Company") was incorporated in the
State of  California  in 1989 under the name of EROX  Corporation.  The  Company
changed the name to Human Pheromone  Sciences,  Inc. in May 1998. The Company is
engaged in the research, development,  manufacturing, marketing and licensing of
consumer  products  containing  synthetic human  pheromones as a component.  The
Company  initiated  commercial  operations  in  late  1994  with a line  of fine
fragrances and toiletries.

Basis of Presentation

         The accompanying  unaudited consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for interim
financial information and with the instructions to Form 10-QSB and Rule 10-01 of
Regulation  S-X.  Accordingly,  they do not include all of the  information  and
footnotes  required by generally  accepted  accounting  principles  for complete
financial statements. In the opinion of management,  all adjustments (consisting
of normal recurring accruals)  considered necessary for a fair presentation have
been included.  Operating  results for the three and nine months ended September
30, 2000 are not necessarily  indicative of the results that may be expected for
the calendar year ending  December 31, 2000. For further  information,  refer to
the  consolidated  financial  statements and footnotes  thereto  included in the
Company's annual report on Form 10-KSB for the year ended December 31, 1999.

Inventories

         Inventories  are  stated  at the  lower of cost  (first  in - first out
method) or market.  The  inventory  at September  30, 2000  consists of finished
goods  inventory  valued  at  $264,000,  work in  process  of  $13,000,  and raw
materials of $91,175.  At December  31,  1999,  these  balances  were  $662,000,
$472,000 and $1,170,000, respectively.

Capital Stock and Stock Options

On September  30, 2000 the Company  sold 1,149  shares of Series BB  convertible
preferred stock for $100,000,  net of issuance costs, to a current  shareholder.
The sale  enabled  the  Company's  net equity to remain in  compliance  with the
NASDAQ  Small Cap  listing  requirements.  No  assurances  can be given that the
Company will remain in compliance with these listing requirements in the future.

         On June 30, 2000 the Company  sold 526 shares of Series BB  convertible
preferred stock for $50,000,  net of issuance  costs, to a current  shareholder.
The sale  enabled  the  Company's  net equity to remain in  compliance  with the
NASDAQ Small Cap listing requirements.

         On  March  26,  2000  the  Company  sold  2,271  shares  of  Series  BB
convertible  preferred  stock for $260,000,  net of issuance costs, to a current
shareholder. The cash was used to reduce bank borrowings.

         Outstanding  options to  purchase  shares of common  stock and  certain
common stock  equivalents were excluded from the computation of diluted earnings
per share since their effect would be antidilutive.

         During the three months ended September 30, 2000,  208,000 common stock
options were granted,  no issued  options were  exercised and options for 16,000
shares were cancelled in connection with employee terminations.


                                       7
<PAGE>


License and Supply Revenue

         On April 24, 2000 the Company entered into a multi-year agreement under
which it licensed its Realm(R) fragrance and toiletry brands to Niche Marketing,
Inc. in exchange for a royalty on Niche Marketing  sales.  The license  includes
all territories excluding the Far East, which the company retains. The effective
date for this agreement was May 1, 2000.

         The sale of the Company's patented pheromones to licensees are reported
when the license fee  revenues  are earned  ratably  based upon the sales of the
licensee or, if miniumum royalties are provided for in the particular agreement,
based on a guaranteed annual minimum payment due from the licensee on a straight
line basis over the applicable twelve month period.


                                       8
<PAGE>


Item 2. Management's Discussion and Analysis of Financial Conditions and Results
        of Operations

         This report contains  forward-looking  statements within the meaning of
Section 27A of the  Securities  Act of 1933, as amended,  and Section 21E of the
Securities  Exchange  Act  of  1934,  as  amended.  Except  for  the  historical
information contained in this discussion and analysis of financial condition and
results  of  operations,  the  matters  discussed  herein  are  forward  looking
statements.  These forward looking statements include but are not limited to the
Company's  plans for sales  growth and  expansion  into new  channels  of trade,
expectations  of gross  margin,  expenses,  new  product  introduction,  and the
Company's   liquidity  and  capital  needs.  These  matters  involve  risks  and
uncertainties  that could cause  actual  results to differ  materially  from the
statements made. In addition to the risks and  uncertainties  described in "Risk
Factors",  below,  these risks and  uncertainties  may include  consumer trends,
business cycles,  scientific  developments,  changes in governmental  policy and
regulation,  currency  fluctuations,  economic  trends in the United  States and
inflation. These and other factors may cause actual results to differ materially
from those anticipated in forward-looking statements.  Readers are cautioned not
to place undue reliance on these forward-looking statements, which speak only as
of the date hereof.

Risk Factors

         The  Company's  future  results  may be affected to a greater or lesser
degree by the following factors among others:

         The Company's marketing strategy may not be successful. The Company may
not be able to successfully  complete  negotiations  for licensing its pheromone
technology.  The Company may not be able to establish and maintain the necessary
sales and  distribution  channels.  The Company may not have sufficient funds to
successfully  market its  products  if the  current  marketing  strategy  is not
successful.

         The Company and/or its licensees may not be able to effectively compete
with larger  companies or with new products.  The prestige  fragrance  market is
extremely  competitive.  Many  fragrance  products  are  better  known  than the
Company's  products and compete for  advertising  and retail  shelf space.  Many
competitors have significantly greater resources that will allow them to develop
and  introduce  new  competing  products or increase  the  promotion  of current
products.

         The  product  life cycle of a  fragrance  can be very  short.  Changing
fashions  and fads can  dramatically  shift  consumer  preferences  and demands.
Traditional  fragrance  companies  introduce a new  fragrance  every year or so.
Changing  fashions and new products may reduce the chance of creating  long-term
brand loyalty to the Company's products.

         The  current  retail  environment  may cause  pricing  and  promotional
pressures.  Five  companies  control  the  majority  of the  sales  in the U. S.
department  store arena.  Because of their market share,  each company will have
significant power to determine the price and promotional terms which the Company
and/or its licensees  must meet in order to sell its products in the  department
stores.

         Seasonality  in sales  may cause  significant  variation  in  quarterly
results.  Sales in the  fragrance  industry are  generally  seasonal  with sales
higher in the second half of the year  because of  Christmas.  This  seasonality
could  cause  a  significant  variation  in the  Company's  quarterly  operating
results.

         The Company has reported  operating  losses in past years. No assurance
can be given that the Company will produce operating income in the future.

         The Company may not be able to protect its technology or trade secrets.
The  Company's  patents and patent  applications  may not protect the  Company's
technology or ensure that the Company's  technology does not infringe  another's
valid  patent.  Others  may  independently   develop  substantially   equivalent
proprietary information.  The Company may not be able to protect its technology,
proprietary information or trade secrets.

         The Company may not be able to recruit  and retain key  personnel.  The
Company's  success  substantially  depends upon  recruiting  and  retaining  key
employees and  consultants  with  research,  product  development  and marketing
experience.  The Company may not be successful in recruiting and retaining these
key people.


                                       9
<PAGE>


         The Company relies upon other  companies to  manufacture  its products.
The  Company  relies  upon  Pherin  and  other   companies  to  manufacture  its
pheromones,  supply  components,  and to blend,  fill and package its  fragrance
products.   The  Company  may  not  be  able  to  obtain  or  retain  pheromones
manufacturers,  fragrance  suppliers,  or component  manufacturers on acceptable
terms.  If not, the Company may not be able to obtain  commercial  quantities of
its products. This would adversely affect operating results.

Results of Operations

Three  Months  ended  September  30,  2000  compared to the Three  Months  ended
September 30, 1999

         Net revenues for the third quarter of 2000 were $501,000 representing a
decrease of 76% from revenues of $2,124,000  for the prior year's  quarter.  The
entire decrease is due to the absence of Realm(R)  product sales for the quarter
due to licensing of the Realm(R)  product line to Niche Marketing  effective May
1, 2000. The license and supply of pheromones under license agreements increased
21% to $282,000 for the current year period.  The  increased  license and supply
revenue is due to the Niche Marketing license revenue.

         Net revenues for the quarters ended September 30, 2000 and 1999 were as
follows (in thousands).

------------------------------------------------------------------------
Markets                                            2000            1999
------------------------------------------------------------------------

  U.S. Retail & Distributor Markets        $         54     $     1,689
  License and Supply Revenues                       282             232
  International Markets                             165             203
                                            ------------     -----------

  Net Revenues                             $        501     $     2,124


         Gross profit for the quarter  ended  September 30, 2000 declined 73% to
$331,000 from $1,204,000 in the prior year due to the reduced sales volume. As a
percentage  of sales, gross  profit  of 66% was  better  than  last  year of 57%
reflecting the impact of the more profitable license and supply business.

         Research and  Development  expenses for the third  quarters of 2000 and
1999 were $80,000 and $82,000,  respectively.  These costs  principally  reflect
payments and costs under the Company's consulting agreements in this area.

         Selling,  general and  administrative  expenses  decreased  $865,000 to
$330,000 in the third  quarter of 2000 from  $1,195,000  in the third quarter of
1999.  Advertising,  selling, and marketing expenses were $765,000 less than the
prior year as the licensee of the Realm(R) brand began  incurring these expenses
May 1,2000.  Distribution  expenses  were  reduced by  $76,000,  and general and
administrative  costs were  $24,000  lower in the current  year's  quarter.  The
Company  relocated  during the  current  quarter to  facilities  that are better
suited to the  restructured  organization,  and  consistent  with the  effort to
reduce the  overhead  required  to support  its  efforts to focus on new product
development, and license opportunities for the patented pheromone technology.

         The Company  incurred no net interest  expense during the third quarter
of 2000,  and $24,000 in the third  quarter of 1999. As a result of the licensee
agreement,   and  subsequent  sale  of  inventory,  the  Company  paid  off  the
outstanding balance on its bank line in April 2000.

Nine Months  ended  September  30,  2000 as  compared  to the Nine Months  ended
September 30, 1999

         Net  revenues  for the  nine  months  ended  September  30,  2000  were
$2,785,000. This was a 57% decrease from net revenues of $6,474,000 for the nine
months of 1999.  The  decreased  revenues are due to the lack of Realm(R)  brand
products sales since May 1, the effective date of the license agreement, and the
22% sales  decrease  recorded in the first four months of the year.  The license
and supply  revenues  increased by $114,000 for the first


                                       10
<PAGE>


nine months of 2000 to $810,000. The Company realized nine months of license and
supply revenue in 2000 as compared with 1999 which reflected the commencement of
licensing revenue in March.

         Net sales for the six months ended  September  30, 2000 and 1999 are as
follows:

-------------------------------------------------------------------------
Markets                                              2000         1999
-------------------------------------------------------------------------

  U.S. Retail & Distributor Markets              $    1,587     $  5,324
  License and Supply Revenues                           810          696
  International Markets                                 388          454
                                                 -----------    ---------

  Net Revenues                                   $    2,785     $  6,474


         Gross  profit  for  the  first  nine  months  of 2000  declined  52% to
$1,929,000  from $4,018,000 in 1999. The decrease is the result of reduced sales
volume. Gross profit as a percentage of revenues improved to 69% compared to 62%
in 1999, also  reflecting the impact of the more  profitable  license and supply
business.

         Research and  Development  expenses for the first half of 2000 and 1999
were  $241,000  and  $249,000,  respectively  and are  principally  comprised of
payments under the Company's contract with Pherin Corporation.

         Selling, general and administrative expenses decreased to $2,108,000 in
the nine months ended  September  30, 2000 from  $4,396,000  in the period ended
September 30, 1999.  Selling marketing and advertising  accounted for $1,922,000
of the decrease with all other  operational  areas spending less in 2000 than in
1999. The reduction in operating  expenses of $2,288,000 is directly  related to
the Company's  decision to license the Realm(R) brand and eliminate the expenses
associated with directly to distributing with the department store accounts.

         The loss from operations decreased by $207,000 to $420,000 for the nine
months ended September 30, 2000, from $627,000 in 1999. The Company's  licensing
of the Realm(R) brand has resulted in reduced net revenues  offset by savings in
operating  expenses that have  significantly  reduced the operating losses.  The
unprofitable  department  store sales channel has been  eliminated  and replaced
with a minimum royalty revenue source.

         The Company  incurred  $16,000 of net interest expense during the first
nine months of 2000 compared to $70,000 net interest  expense in 1999 due to the
repayment of the credit line borrowings in April 2000.

LIQUIDITY

         At September 30, 2000, the Company had no outstanding  borrowings,  and
working  capital  was  $1,990,000.  At  December  31,  1999 the  Company had net
borrowings of $900,000 and working capital of $2,052,000. For the nine months of
2000, net cash generated  from operating  activities was $1,378,000  compared to
$908,000  used  in  operating  activities  for the  prior  year's  nine  months.
Accordingly,  the Company had a net  repayment of its line of credit of $900,000
in the first nine  months of 2000,  while it had net  additional  borrowings  of
$426,000 in the same period of 1999.

         On  July  1,  2000,   the  Company's   Business  Loan   Agreement  with
Mid-Peninsula  Bank  of Palo  Alto,  California  (the  "Bank")  providing  for a
continued line of credit expired. The Company may apply for a new credit line in
the future.

         Assuming the Company's activities proceed substantially as planned, the
Company's cash proceeds from the license to Niche  Marketing,  license  revenues
and  anticipated  revenues  from  product  sales  should be adequate to meet its
working capital needs over the next twelve months.  Working capital requirements
will primarily be for research, product development and administrative costs.

         Additional  working  capital may be required should the Company fail to
generate new products or new license revenues.  Furthermore,  additional working
capital may be required  should the Company  experience  a greater  than planned
success  with  its   products,   potential   products,   and  research   funding
requirements.  Funds would


                                       11
<PAGE>


be needed for  inventory  build,  accounts  receivable  financing  and  staffing
purposes.  If the  Company  fails to achieve  revenues  from its 2000  marketing
efforts,  or if product  development  proves to be more capital  intensive  than
planned, the Company may require additional funding.

         On September 30, 2000, the Company obtained $100,000  additional equity
capital from a current  shareholder by issuing  shares of convertible  preferred
stock.

RECENT ACCOUNTING PRONOUNCEMENTS

         In June 1998, the FASB issued SFAS No. 133,  "Accounting for Derivative
Instruments  and  Hedging  Activities".  SFAS  No.  133  requires  companies  to
recognize  all  derivatives  contracts as either  assets or  liabilities  in the
balance sheet and to measure them at fair value. If certain  conditions are met,
a derivative may be specifically  designated as a hedge,  the objective of which
is to match the timing of gain or loss  recognition  on the  hedging  derivative
with the recognition of (i) the changes in the fair value of the hedged asset or
liability that are  attributable  to the hedged risk or (ii) the earnings effect
of the hedged  forecasted  transaction.  For a derivative  not  designated  as a
hedging  instrument,  the gain or loss is  recognized in income in the period of
change.  SFAS No. 133, as amended by SFAS No. 137, is  effective  for all fiscal
quarters of fiscal quarters of fiscal years beginning after June 15, 2000.

         The Company has not entered into derivatives  contracts either to hedge
existing risks or for speculative  purposes.  Accordingly,  the Company does not
expect  adoption of the new standard on January 1, 2001 to affect its  financial
statements.

         In December  1999, the SEC issued Staff  Accounting  Bulletin (SAB) No.
101, Revenue Recognition in Financial Statements. SAB No. 101 summarizes certain
of the staff's views in applying  generally  accepted  accounting  principles to
revenue  recognition in financial  statements.  SAB No. 101 is effective for all
transactions  beginning with the second quarter of 2000. The Company has applied
SAB No. 101 where applicable.


                                       12
<PAGE>




                                     PART II

                                OTHER INFORMATION


Item 6.  Exhibits and Reports on Form 8-K
------   --------------------------------

(a)      Exhibit 27.01-Financial Data Schedule


                                       13
<PAGE>


                                   SIGNATURES

         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  registrant  had duly  caused  this  Report  to be  signed  on behalf by the
undersigned thereunto duly authorized.

                                           HUMAN PHEROMONE SCIENCES, INC.

                                           Registrant

Date:  November 13, 2000                   /s/ William P. Horgan
                                           -----------------------------------
                                           William P. Horgan
                                           Chairman and Chief Executive Officer




Date:  November 13, 2000                   /s/ Gregory S. Fredrick
                                           -----------------------------------
                                           Gregory S. Fredrick
                                           Vice President Finance


                                       143